DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

Karyopharm Therapeutics (NASDAQ: KPTI)

39.57 -0.13 (-0.33%)

Quote as of


company name or ticker

Recent Quotes

KPTI $39.57 -0.33%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $39.90
Previous Close $39.70
Daily Range $38.76 - $40.40
52-Week Range $15.50 - $47.98
Market Cap $1.3B
P/E Ratio -32.54
Dividend (Yield) $0.00 (0.0%)
Volume 1,036,669
Average Daily Volume 145,395
Current FY EPS -$2.18

Sector

Industry

Karyopharm Therapeutics (KPTI) Description

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Website: http://www.karyopharm.com/

News & Commentary

Why DreamWorks Animation, Vertex Pharmaceuticals, and Karyopharm Therapeutics Tumbled Today

The stock market held up fine on Monday, but these stocks didn't do as well. Find out why.

Karyopharm Therapeutics' (KPTI) CEO Michael Kauffman on Q2 2014 Results - Earnings Call Transcript

Karyopharm Theraputics: Will It Be An EPIX Fail?

Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc. ...

InsiderInsights.com Daily Round Up: 7/2/14

Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Tale of the Tape

US Stock Futures Drop Ahead Of Consumer Sentiment Report

A Beaten-Down Biotech Stock Poised for an Epic Short Squeeze

Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog

Why Karyopharm Therapeutics Inc. Shares Swooned

Karyopharm dips after receiving a bark of approval from the Food and Drug Administration. Find out if this dip is a buying opportunity or a sign to stick to the sidelines.

See More KPTI News...